Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Wirth

Showing results (561-570 of 675) with videos related to

Pageof 68
Sort By:
The Oncologist|September 13, 2021
Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO-001 TrialLori J Wirth, Bruce Robinson, Valentina Boni, et al.
Urologic Oncology|September 26, 2016
The effect of HER2 status on oncological outcomes of patients with invasive bladder cancerFrancesco Soria, Marco Moschini, Andrea Haitel, et al.
Thyroid : Official Journal of the American Thyroid Association|April 16, 2020
Response to RET-Specific Therapy in <i>RET</i> Fusion-Positive Anaplastic Thyroid CarcinomaDora Dias-Santagata, Jochen K Lennerz, Peter M Sadow, et al.
Endocrine|February 4, 2017
Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomesRobert I Haddad, Martin Schlumberger, Lori J Wirth, et al.
The Journal of Clinical Endocrinology and Metabolism|August 23, 2016
Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid CancerBruce Robinson, Martin Schlumberger, Lori J Wirth, et al.
Future Oncology (London, England)|August 15, 2022
LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve <i>RET</i>-mutant medullary thyroid cancerLori J Wirth, Marcia S Brose, Rossella Elisei, et al.
Cancer|August 16, 2016
Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancerSteven I Sherman, Douglas O Clary, Rossella Elisei, et al.
Journal of Medical Genetics|May 5, 1999
Systematic characterisation of disease associated balanced chromosome rearrangements by FISH: cytogenetically and genetically anchored YACs identify microdeletions and candidate regions for mental retardation genesJ Wirth, H G Nothwang, S van der Maarel, et al.
Human Molecular Genetics|February 13, 2001
A translocation breakpoint cluster disrupts the newly defined 3' end of the SNURF-SNRPN transcription unit on chromosome 15J Wirth, E Back, A Hüttenhofer, et al.
Development (Cambridge, England)|August 26, 2011
Cell class-specific regulation of neocortical dendrite and spine growth by AMPA receptor splice and editing variantsMohammad I K Hamad, Zhan-Lu Ma-Högemeier, Christian Riedel, et al.
Pageof 68

Showing results (561-570 of 675) with videos related to

Sort By:
Pageof 68
The Oncologist|September 13, 2021
Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO-001 TrialLori J Wirth, Bruce Robinson, Valentina Boni, et al.
Urologic Oncology|September 26, 2016
The effect of HER2 status on oncological outcomes of patients with invasive bladder cancerFrancesco Soria, Marco Moschini, Andrea Haitel, et al.
Thyroid : Official Journal of the American Thyroid Association|April 16, 2020
Response to RET-Specific Therapy in <i>RET</i> Fusion-Positive Anaplastic Thyroid CarcinomaDora Dias-Santagata, Jochen K Lennerz, Peter M Sadow, et al.
Endocrine|February 4, 2017
Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomesRobert I Haddad, Martin Schlumberger, Lori J Wirth, et al.
The Journal of Clinical Endocrinology and Metabolism|August 23, 2016
Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid CancerBruce Robinson, Martin Schlumberger, Lori J Wirth, et al.
Future Oncology (London, England)|August 15, 2022
LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve <i>RET</i>-mutant medullary thyroid cancerLori J Wirth, Marcia S Brose, Rossella Elisei, et al.
Cancer|August 16, 2016
Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancerSteven I Sherman, Douglas O Clary, Rossella Elisei, et al.
Journal of Medical Genetics|May 5, 1999
Systematic characterisation of disease associated balanced chromosome rearrangements by FISH: cytogenetically and genetically anchored YACs identify microdeletions and candidate regions for mental retardation genesJ Wirth, H G Nothwang, S van der Maarel, et al.
Human Molecular Genetics|February 13, 2001
A translocation breakpoint cluster disrupts the newly defined 3' end of the SNURF-SNRPN transcription unit on chromosome 15J Wirth, E Back, A Hüttenhofer, et al.
Development (Cambridge, England)|August 26, 2011
Cell class-specific regulation of neocortical dendrite and spine growth by AMPA receptor splice and editing variantsMohammad I K Hamad, Zhan-Lu Ma-Högemeier, Christian Riedel, et al.
Pageof 68